SEE FULL COMPANY PROFILES WITH A FREE TRIAL
EMIS is the definitive emerging markets news, research, company, and financial data resource. EMIS - ISI Emerging MarketsLEARN MORE
Search for another company:
ALL
Croatia
facebook Please check the full coverage of information what EMIS can offer you. SEE SAMPLE

Company Information

Full name
PLIVA HRVATSKA d.o.o. za razvoj, proizvodnju i prodaju lijekova i farmaceutskih proizvoda

Headquarters
Prilaz baruna Filipovica 25; Zagreb; Zagrebacka and town Zagreb; 10000
Status: Non-Listed
Legal Form: Limited Liability Company
Operational Status: Operational
NIN: 3214052
Financial Auditors: RAIFFEISENBANK AUSTRIA d.d. (2011)
Incorporation Date: January 1, 2003
Total Employees: 1,914

Tel: 01/3720000

Company Description

Manufacture and distribution of pharmaceuticals;Research and development of new pharmaceuticals;After taking over production and distribution from PLIVA d.d., PLIVA HRVATSKA became the largest pharmaceutical company and biggest exporter in Croatia;Exports all over the world: Belarus, Czech Republic, Germany, Switzerland, France, Great Britan, Italy, Hungary, Macedonia, Bosnia and Hercegovina, Slovenia, USA etc. Brands: Andol, Andol 100, Atrocam, Betrion, Cilazil, Diklonat, Gastal, Geokorton, Geonistin,
More

Company Analysis

According to the Individual - Audited financial statement for the Year of 2010, total net operating revenues decreased with -2.42%, from HRK 2,779,505 thousands to HRK 2,712,171.71 thousands. Operating Results increased from HRK -94,867 thousands to HRK 608,080.51 thousands. The results of the period increased 968.85% reaching HRK 555,019.89 thousands at the end of the period against HRK 51,927 thousands last year. Return on equity (Net income/Total equity) went from 1.42% to 13.12%, the Return On Asset (Net income / Total Asset) went from 1.22% to 11.61% and the Net Profit Margin (Net Income/Net Sales) went from 1.87% to 20.46% when compared to the same period of last year. The Debt to Equity Ratio (Total Liabilities/Equity) was 12.98% compared to 16.25% of last year. Finally, the Current Ratio (Current Assets/Current Liabilities) went from 4.08 to 4.05 when compared to the previous year.

Key Executives

Matko Bolanca Chairman of the Management Board
More

Companies with Similar Main Activities

ISI Emerging Markets

FULL COMPANY PROFILE

Please check the full coverage of information what EMIS can offer you.
SEE SAMPLE
SELECT CURRENCY
Balance Sheet

Total Assets

4,778,821

4,243,947

Current Assets

X,XXX,XXX

X,XXX,XXX

Total Liabilities

XXX,XXX

XXX,XXX

Shareholders Equity

X,XXX,XXX

X,XXX,XXX

Current Liabilities

XXX,XXX

XXX,XXX

* All the accounts are in HRK.
Income Statement

Total Revenues

X,XXX,XXX

X,XXX,XXX

Operational Profit (Loss)

XXX,XXX

-XX,XXX

Net Profit (Loss)

XXX,XXX

XX,XXX

* All the accounts are in HRK.
Ratios
Profitability Ratios

Return on Assets (ROA)

XX.XX%

X.XX%

Annualised Return on Assets (ROA)

XX.XX%

X.XX%

Return on Equity (ROE)

XX.XX%

X.XX%

Annualised Return on Equity (ROE)

XX.XX%

X.XX%

Return on Sales (ROS)

XX.XX%

X.XX%

Return on Capital

XX.X%

X.XX%

Gross Profit Margin

XX.XX%

XX.XX%

Operating Profit Margin

XX.XX%

XX.XX%

Efficiency Ratios

Accounts Receivable Turnover

X.XXx

X.XXx

Inventory Turnover

X.XXx

X.XXx

Current asset turnover

X.XXx

X.XXx

Fixed-asset turnover

X.XXx

X.XXx

Asset Turnover

X.XXx

X.XXx

Valuation figures and ratios

Earning Before Interests and Taxes (EBIT)

XXX,XXX

-XX,XXX

EBITDA

XXX,XXX

XXX,XXX

Bookvalue (BV)

X,XXX,XXX

X,XXX,XXX

Net Cash

XXX,XXX

XXX,XXX

Liquidity Ratios

Current Ratio

XXX.XX%

XXX.X%

Quick ratio

XXX.XX%

XXX.XX%

Doom's day ratio

XX.XX%

XX.XX%

Leverage Ratios

Leverage ratio

XXX.XX%

XXX.XX%

Debt to equity

XX.XX%

XX.XX%

Debt to total assets

XX.XX%

XX.XX%

Long Term Debt to Capital

X.XX%

X.XX%

Trend Ratios

Revenue Trend

XX.XX%

XXX.XX%

Net Income Trend

X,XXX.XX%

XXX.XX%

Operating Income Trend

XX.XX%

XX.XX%